

## Mepact: a chance to leave osteosarcoma in the past

- ... the **first therapy** shown to increase survival rates in osteosarcoma for over 20 years<sup>1</sup>
- ... **significantly increased overall survival by 8%** (in combination with chemotherapy, compared with chemotherapy alone)<sup>2</sup>
- ... has demonstrated a predictable, **manageable tolerability profile**, with side effects largely related to immune activation<sup>3-5</sup>

Prescribing information

**Local PI to be added in accordance with local laws and regulations**

#### References

1. Meyers PA, et al. *Expert Rev Anticancer Ther* 2009; 9: 1035-1049.
2. Meyers PA, et al. *J Clin Oncol* 2008; 26: 633-638.
3. European Medicines Agency. Available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Public\\_assessment\\_report/human/000802/WC500026564.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000802/WC500026564.pdf). [Accessed February 2016].
4. Mepact Summary of Product Characteristics.
5. Anderson P. *Future Oncol* 2006; 2: 333-343.
6. Anderson P et al. *Pediatric Blood Cancer* 2013; 61 (2):238-44.

Job code: GLO/MEP/2016-00001  
Date of preparation: February 2016



## Mepact: shown to improve patients' chance of a future<sup>2</sup>

In combination with chemotherapy, compared with chemotherapy alone:<sup>2</sup>




Mepact showed an increase in patients' six-year overall survival rates from **70 to 78%** (p=0.03)



Mepact showed a decrease in the relative risk of death by **29%** (hazard ratio 0.71, 95% CI: 0.52-0.96)

## Overall survival



Adapted from Meyers et al. 2008

## Mepact demonstrated a predictable, manageable tolerability profile<sup>3,4</sup>

### When used in combination with chemotherapy in Phase III studies:

- Mild to moderate side effects<sup>4</sup>
- Which were largely related to immune activation and the resulting biological activity<sup>3-5</sup>

The most frequent grade 3 and 4 AEs were typically those associated with intensive chemotherapy: stomatitis, nausea, vomiting, abnormal liver enzymes, low blood counts and infections
- Hearing loss was the only AE that occurred at a higher frequency with Mepact combined with chemotherapy compared to chemotherapy alone<sup>3</sup>